SV102 · SV-Delivery™
SV102 Delivery™ Human T cell targeted LNP
Species
Human
Primary target
T cell (human · pan-T)
Applications
in vitro / ex vivo
Cargo compatibility
mRNA, saRNA
Particle size
80-100 nm
Freeze-thaw cycles tested
3
Data we are still collecting for SV102
SunVax has not yet publicly disclosed efficacy, dose, or stability numbers for this kit at the same depth as SV101 / SV106. Rather than fill the table with inferred (grade C) numbers, we leave it explicit:
- No published in vitro transfection percentage for the primary target cell.
- No published in vivo (animal model) decay curve.
- No public freeze-thaw stability cycle count.
- No public encapsulation efficiency on this kit's lot.
If you need any of these data points to plan an experiment, contact the SunVax partnership team — they will share what is available under NDA.
Published efficacy
Each result is shown with its evidence grade and source. Grade D entries are not displayed in production.
| Assay | Result | Grade | Source |
|---|
Recommended in vitro dose
5-15 μg mRNA / 10⁶ cells (range 待 SunVax 确认)
Known limitations
Honest disclosure: these are gaps in current SunVax data, not intended performance claims.
- Human in vivo 数据仍待 build
- Mouse data 不可直接外推
Sources used on this page
- SunVax conference presentation 2026-05-03 · slide 2 (kits portfolio) and slide 3 (efficacy / stability data).
- SunVax product catalog at sunvaxmrna.com (last verified 2026-05-16).
- Per-result citations are shown in the "Published efficacy" table above with their evidence grade.
To request a correction or to ask for additional documentation on this kit, email [email protected].